Toevoegen aan een lijst
PDF-rapport : Royalty Pharma plc
Beurs gesloten -
Andere beurzen
|
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | |
27,07 USD | +0,63% | -0,40% | -31,50% |
28/11 | Transcript : Royalty Pharma plc Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-28-2023 03:00 PM | CI |
22/11 | MORPHOSYS IN FOCUS: Het geschokte geloof in een blockbuster | DP |
Vakgebied
Verkoop per activiteit
USD in miljoenen | 2021 | Gewicht | 2022 | Gewicht | Delta |
---|---|---|---|---|---|
Biopharmaceutical Royalties
100,0
%
| 2 289 | 100,0 % | 2 237 | 100,0 % | -2,28% |
Verkoop per regio
USD in miljoenen | 2021 | Gewicht | 2022 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 2 289 | 100,0 % | 2 237 | 100,0 % | -2,28% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Pablo Legorreta
CEO | Chief Executive Officer | 59 | 1996 |
Terrance Coyne
DFI | Director of Finance/CFO | 41 | 2010 |
George Lloyd
CIO | Chief Investment Officer | 63 | 2011 |
Arthur McGivern
CIO | Chief Investment Officer | - | 2022 |
Sara Klymkowsky
CTO | Chief Tech/Sci/R&D Officer | - | 2012 |
James Reddoch
CTO | Chief Tech/Sci/R&D Officer | 53 | 2008 |
Christopher Hite
BRD | Director/Board Member | 56 | 2020 |
George Grofik
IRC | Investor Relations Contact | - | 2020 |
Human Resources Officer | - | 2020 | |
Sarah Cata
TRE | Treasurer | - | 2014 |
Bestuurders
Bestuurders | Titel | Leeftijd | Van |
---|---|---|---|
Rory Riggs
FOU | Founder | 70 | 1996 |
Errol de Souza
BRD | Director/Board Member | 69 | 2020 |
David Hodgson
BRD | Director/Board Member | 66 | 2022 |
Ted Love
BRD | Director/Board Member | 64 | 2020 |
Henry Fernandez
BRD | Director/Board Member | 64 | 2020 |
Gregory Norden
BRD | Director/Board Member | 65 | 2020 |
Pablo Legorreta
CEO | Chief Executive Officer | 59 | 1996 |
Mario Giuliani
BRD | Director/Board Member | 51 | 2020 |
Bonnie Bassler
BRD | Director/Board Member | 60 | 2020 |
Christopher Hite
BRD | Director/Board Member | 56 | 2020 |
Aandelenklasse
Stemming | Aantal | Percentage vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 446 688 809 | 424 536 544 ( 95,04 %) | 0 | 95,04 % |
Aandeel B | 1 | 152 546 000 | 0 | 0 | |
Aandeel C | 0 | 50 000 | 0 | 0 |
Bedrijfsgegevens
Royalty Pharma Plc
110 East 59th Street 33rd floor
10022, New York
+212 883 0200
http://www.royaltypharma.com
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
Royalty Pharma Holdings Ltd.
|
Finance - Financial Conglomerates
|
Sector
Trading rating :
Beleggingsrating :
ESG Refinitiv :
B-
Verkoop
Koop

Gemiddeld advies
Kopen
Aantal analisten
8
Laatste slotkoers
27,07USD
Gemiddelde koersdoel
47,88USD
Spread / Gemiddelde doel
+76,86%
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-31,50% | 11 967 M $ | |
+61,56% | 532 md. $ | |
+48,29% | 452 md. $ | |
-12,45% | 366 md. $ | |
-7,63% | 256 md. $ | |
-11,89% | 245 md. $ | |
-18,74% | 217 md. $ | |
+1,83% | 199 md. $ | |
-9,73% | 197 md. $ | |
-40,53% | 170 md. $ |
- Beurs
- Aandelen
- Aandeel Royalty Pharma plc - Nasdaq
- Onderneming Royalty Pharma plc